Lhermitte, L
,
Mejstrikova, E
van der Sluijs-Gelling, A J
Grigore, G E
Sedek, L
Bras, A E
Gaipa, G
Sobral da Costa, E
Novakova, M
Sonneveld, E
Buracchi, C
de Sá Bacelar, T
te Marvelde, J G
Trinquand, A
Asnafi, V
Szczepanski, T http://orcid.org/0000-0001-5336-261X
Matarraz, S
Lopez, A
Vidriales, B
Bulsa, J
Hrusak, O
Kalina, T http://orcid.org/0000-0003-4475-2872
Lecrevisse, Q
Martin Ayuso, M
Brüggemann, M
Verde, J
Fernandez, P http://orcid.org/0000-0003-3237-6283
Burgos, L
Paiva, B
Pedreira, C E
van Dongen, J J M
Orfao, A
van der Velden, V H J
Article History
Received: 27 July 2017
Revised: 29 September 2017
Accepted: 9 October 2017
First Online: 1 November 2017
Competing interests
: JJMvD: contract research for Roche, Amgen and BD Biosciences. VHJvdV: contract research for Roche, Amgen, Pfizer, Janssen and BD Biosciences; consultancy fees: Celgene. TS: a member of a Scientific Advisory Board for JazzPharma, Novartis; reimbursement for attending symposia organized by CSL Behring, Novartis, Pfizer, Alexion, Shire and JazzPharma. GEG and MMA are employees of Cytognos SL, Salamanca, Spain. The other authors declare no conflict of interest.